EGFR and non-small cell lung carcinoma: While accumulating evidence has shown that the malfunctions of EGFR caused by activating mutations initiate constitutive engagement and activation of downstream effector signaling, which account for approximately 10~30% oncogenesis of non-small cell lung cancer (NSCLC) [30,31].